Please use this identifier to cite or link to this item:
http://acervodigital.unesp.br/handle/11449/67779
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Viegas Jr., Cláudio | - |
dc.contributor.author | Bolzani, Vanderlan da Silva | - |
dc.contributor.author | Furlan, Maysa | - |
dc.contributor.author | Manssour Fraga, Carlos Alberto | - |
dc.contributor.author | Barreiro, Eliezer J. | - |
dc.date.accessioned | 2014-05-27T11:21:06Z | - |
dc.date.accessioned | 2016-10-25T18:19:41Z | - |
dc.date.available | 2014-05-27T11:21:06Z | - |
dc.date.available | 2016-10-25T18:19:41Z | - |
dc.date.issued | 2004-07-01 | - |
dc.identifier | http://dx.doi.org/10.1590/S0100-40422004000400021 | - |
dc.identifier.citation | Quimica Nova, v. 27, n. 4, p. 655-660, 2004. | - |
dc.identifier.issn | 0100-4042 | - |
dc.identifier.uri | http://hdl.handle.net/11449/67779 | - |
dc.identifier.uri | http://acervodigital.unesp.br/handle/11449/67779 | - |
dc.description.abstract | Alzheimer's disease (AD) is a progressive neurodegenerative pathology with severe economic and social impact. There is currently no cure, although cholinesterase inhibitors provide effective temporary relief of symptoms in some patients. Nowadays drug research and development are based on the cholinergic hypothesis that supports the cognition improvement by regulation of the synthesis and release of acetylcholine in the brain. There are only four commercial medicines approved for treatment of AD and natural products have played an important role in the research for new acetylcholinesterase inhibitors. | en |
dc.format.extent | 655-660 | - |
dc.language.iso | por | - |
dc.source | Scopus | - |
dc.subject | Acetylcholinesterase | - |
dc.subject | Alzheimer's disease | - |
dc.subject | Natural products | - |
dc.subject | 11 hydroxygalantamine | - |
dc.subject | 9 o norgalantamine | - |
dc.subject | acetylcholine | - |
dc.subject | cholinesterase inhibitor | - |
dc.subject | donepezil | - |
dc.subject | galantamine | - |
dc.subject | Ginkgo biloba extract | - |
dc.subject | natural product | - |
dc.subject | rivastigmine | - |
dc.subject | tacrine | - |
dc.subject | unclassified drug | - |
dc.subject | acetylcholine release | - |
dc.subject | Alzheimer disease | - |
dc.subject | brain function | - |
dc.subject | cholinergic activity | - |
dc.subject | cognition | - |
dc.subject | conference paper | - |
dc.subject | degenerative disease | - |
dc.subject | drug efficacy | - |
dc.subject | drug indication | - |
dc.subject | drug synthesis | - |
dc.subject | economic aspect | - |
dc.subject | hypothesis | - |
dc.subject | neuropathology | - |
dc.subject | regulatory mechanism | - |
dc.subject | social aspect | - |
dc.title | Produtos naturais como candidatos a fármacos úteis no tratamento do mal de Alzheimer | pt |
dc.title.alternative | Natural products as candidates for useful drugs in the treatment of Alzheimer's disease | en |
dc.type | outro | - |
dc.contributor.institution | Universidade Estadual Paulista (UNESP) | - |
dc.contributor.institution | Universidade Federal do Rio de Janeiro (UFRJ) | - |
dc.description.affiliation | Instituto de Química Univ. Estadual Paulista Julio M., CP 355, 14801-970 Araraquara - SP | - |
dc.description.affiliation | Faculdade de Farmácia Univ. Federal do Rio de Janeiro, CP 68006, 21941-590 Rio de Janeiro - RJ | - |
dc.identifier.doi | 10.1590/S0100-40422004000400021 | - |
dc.identifier.scielo | S0100-40422004000400021 | - |
dc.identifier.wos | WOS:000223108900021 | - |
dc.rights.accessRights | Acesso aberto | - |
dc.identifier.file | 2-s2.0-15044356788.pdf | - |
dc.relation.ispartof | Química Nova | - |
dc.identifier.scopus | 2-s2.0-15044356788 | - |
Appears in Collections: | Artigos, TCCs, Teses e Dissertações da Unesp |
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.